Next-Generation Breast Cancer Diagnostic & Screening Market by Product (Accessories, Breast Imaging Systems, Software & Services), Diagnostic Technology (DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics), Screening Technol

Next-Generation Breast Cancer Diagnostic & Screening Market by Product (Accessories, Breast Imaging Systems, Software & Services), Diagnostic Technology (DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics), Screening Technology, Application, End User - Global Forecast 2024-2030

The Next-Generation Breast Cancer Diagnostic & Screening Market size was estimated at USD 22.81 billion in 2023 and expected to reach USD 25.12 billion in 2024, at a CAGR 10.91% to reach USD 47.11 billion by 2030.

Next-generation breast cancer diagnostic & screening technologies represent a paradigm shift in how breast cancer is detected and diagnosed, offering more precise, efficient, and less invasive methods compared to traditional modalities. These advanced technologies, including digital mammography, 3D mammography (tomosynthesis), automated breast ultrasound, and molecular breast imaging, leverage high-end imaging and genomic profiling to identify breast cancers at an early stage when they are most treatable. Major factors driving the adoption of these novel diagnostic tools include the prevalence of breast cancer globally, increased awareness and advocacy for early detection, advancements in imaging technology, and a push toward personalized medicine. Despite their significant importance, these next-generation technologies face utility challenges such as high costs, limited access in low-resource settings, and the potential for overdiagnosis leading to unnecessary treatments. Addressing these restraints requires concerted efforts to reduce costs through technological innovations and scale, improving healthcare infrastructure, and implementing more nuanced screening protocols to balance early detection with the risk of overdiagnosis. Integration of artificial intelligence to improve diagnostic accuracy, the development of portable screening devices to increase access, and the continuous evolution of genomic profiling to predict breast cancer risk and tailor screening strategies accordingly are expected to expand the next-generation breast cancer diagnostic & screening space in the coming years.

Regional Insights

In the Americas, particularly in the United States and Canada, the use of advanced breast cancer diagnostics, including genetic testing and liquid biopsies, is quite prevalent, supported by substantial investments in healthcare technology and a robust framework for early breast cancer detection programs. The region is home to major companies specializing in oncology diagnostics, fostering an environment conducive to the research, development, and commercialization of innovative screening solutions. The APAC region is experiencing rapid growth in the adoption of next-generation diagnostics, driven by increasing awareness and improving healthcare infrastructures in countries such as China, Japan, and India. Local and global players are actively expanding their presence, tailoring products to meet specific population needs. EMEA presents a varied picture, with Western European countries showcasing high adoption rates of advanced diagnostic tools underpinned by favorable healthcare policies and strong public-private healthcare systems. However, Eastern Europe, the Middle East, and Africa face accessibility and affordability issues, though initiatives aimed at improving breast cancer screening rates and the gradual entry of next-gen diagnostics are beginning to make an impact.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Next-Generation Breast Cancer Diagnostic & Screening Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Rising prevalence of breast cancer worldwide
Growing inclination towards early diagnosis and treatment of diseases
Government initiatives to raise awareness regarding breast cancer

Market Restraints

Expensive breast cancer diagnostic & screening technologies

Market Opportunities

Advancements in next-generation breast cancer diagnostic & screening technologies
Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions

Market Challenges

Complexity in manufacturing and stringent regulatory approval process

Market Segmentation Analysis

Product: Need for advanced breast imaging systems for enhanced clinical outcomes
End User: Expanding use of breast cancer diagnostics in hospitals to cater to a wider patient population

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Next-Generation Breast Cancer Diagnostic & Screening Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Next-Generation Breast Cancer Diagnostic & Screening Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection

GE Healthcare unveiled its MyBreastAI Suite, a ground-breaking artificial intelligence (AI) platform designed to revolutionize breast cancer detection and enhance clinical workflows. This innovative suite integrates three sophisticated AI applications from iCAD: ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment, all aimed at supporting early breast cancer detection and improving outcomes for patients.

Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations

Exact Sciences Corp. has announced strategic collaborations with the Broad Institute of MIT and Harvard and Baylor Scott White, aiming to revolutionize patient care by enhancing access to advanced genomic data. Through these partnerships, Exact Sciences is set to leverage the Broad Institute's groundbreaking Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (MAESTRO) technology. This technology offers an ultra-sensitive approach for the detection of molecular residual disease, employing minimal sequencing while maximizing bioinformatic analysis to identify thousands of patient-specific mutations.

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

Pfizer and Thermo Fisher Scientific Inc. have forged a groundbreaking partnership aimed at revolutionizing cancer care by expanding access to next-generation sequencing (NGS) for lung and breast cancer diagnostics in over 30 countries across Latin America, Africa, the Middle East, and Asia. This strategic alliance seeks to counteract the limitations and inaccessibility that have historically marred the provision of advanced genomic testing in these regions. By leveraging Thermo Fisher's expertise in NGS technology, the collaboration is aimed to establish local laboratories equipped with the necessary infrastructure and professional training to uphold stringent industry standards.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Next-Generation Breast Cancer Diagnostic & Screening Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Breast Cancer Diagnostic & Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., ARTIVION INC., Becton, Dickinson and Company, Benitec Biopharma Ltd, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Invivoscribe, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Pfizer Inc., QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Breast Cancer Diagnostic & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Accessories
Breast Imaging Systems
Software & Services
Diagnostic Technology
DNA Microarrays
Lab-on-a-Chip & Reverse Transcriptase-PCR
Molecular Diagnostics
Next Generation Sequencing
Protein Microarrays
qPCR & Multiplexing
Screening Technology
Ionizing Breast Imaging Technologies
3D Breast Tomosynthesis
Analog Mammography
Cone-Beam Computed Tomography (CBCT)
Contrast-Enhanced Mammography (CEM)
Full-Field Digital Mammography (FFDM)
Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
Positron Emission Mammography (PEM)
Positron Emission Tomography and Computed Tomography (PET-CT)
Non-ionizing Breast Imaging Technologies
Automated Whole-Breast Ultrasound (AWBU)
Breast MRI
Breast Thermography
Breast Ultrasound
Electric Impedance Tomography
Optical Imaging
Application
Cancer Screening
Companion Diagnostics
Risk Analysis
Therapeutic Monitoring
End User
Breast Care Centers
Diagnostic Imaging Centers
Hospitals & Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year